期刊
JOURNAL OF BIOMEDICAL RESEARCH
卷 25, 期 5, 页码 299-308出版社
NANJING MEDICAL UNIV
DOI: 10.1016/S1674-8301(11)60041-9
关键词
nitric oxide; L-arginine; arginase; nor-NOHA; nitrosation; nitric oxide synthase
资金
- National Institute of Environmental Health Sciences [T32 ES007058-33]
- CTSC K12 Award [UL1RR024146, KL2RR024144]
- American Asthma Foundation
Exhaled breath nitric oxide (NO) is an accepted asthma biomarker. Lung concentrations of NO and its amino acid precursor, L-arginine, are regulated by the relative expressions of the NO synthase (NOS) and arginase isoforms. Increased expression of arginase I and NOS2 occurs in murine models of allergic asthma and in biopsies of asthmatic airways. Although clinical trials involving the inhibition of NO-producing enzymes have shown mixed results, small molecule arginase inhibitors have shown potential as a therapeutic intervention in animal and cell culture models. Their transition to clinical trials is hampered by concerns regarding their safety and potential toxicity. In this review, we discuss the paradigm of arginase and NOS competition for their substrate L-arginine in the asthmatic airway. We address the functional role of L-arginine in inflammation and the potential role of arginase inhibitors as therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据